RxDoctor Payments Data

Kaitlin Meier

Nurse Practitioner · Milwaukee, WINPI 1194216168

Payments from drug & device makers

$2,856in general payments, 2019–2025

Across 108 payments — averaging $26.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$807
  • Gilead$722
  • AbbVie$531
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$164
  • Takeda Pharmaceuticals U.S.A., Inc.$158
  • Braintree Laboratories, Inc.$99
  • plus $375 from 11 others

What the payments were for

  • Food & beverage$2,61492%
  • Education$2428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,856 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$23,102
Medicare patients
226
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$78,752
LinzessLinaclotide73$59,940
NexiumEsomeprazole Magnesium11$8,781
Omeprazole321$5,371
Pantoprazole Sodium273$4,529
CholestyramineCholestyramine (With Sugar)41$3,174
Dexlansoprazole DrDexlansoprazole16$3,051
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,268
Esomeprazole Magnesium34$1,826
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl101$1,474
Dicyclomine Hcl57$1,456
Budesonide EcBudesonide11$1,241
Budesonide DrBudesonide11$1,160
Sucralfate22$1,066
Colestipol Hcl15$1,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$531$59,94073 claims
Braintree Laboratories, Inc.Sutab$99$2,26814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →